Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

University Hospital Gasthuisberg, Leuven, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:5City/State/Province:Leuven
Treatments:ChemotherapyHospital:University Hospital Gasthuisberg
Drugs:Journal:Link
Date:Aug 2007

Description:

Patients: This phase II study involved 165 patients with stage III/IV or metastatic recurrent non-small-cell lung cancer. All had previously received a platinum-based therapy and about half had previously undergone radiation therapy. The patients ranged in age from 33 to 84 years, and the majority were men.

Treatment: All patients were given the chemotherapy drug Ixabepilone. The patients were divided into two study groups, or arms: arm A was given a single dose of the drug, and arm B was given the drug for 5 days.

Toxicity: Two patients died, one in each study arm. One death was due to pneumonia/respiratory failure; the other to pulmonary pneumonitis, infection, mucositis, confusion, and hypoxia. Grade 4 toxicities mainly affected white blood cells and occurred in 12% of patients or less. Two patients had grade 4 febrile neutropenia, one patient had grade 4 sensory neuropathy and one case of grade 4 dyspnea.

Results: The median overall survival in Arm 1 was 8.3 months and 7.3 months in Arm B. Twenty-two patients survived longer than two years.

Support: Authors received research funds from Bristol-Meyers Squibb, Eli Lilly & Co., EMD Pharmaceuticals, Imclone, GlaxoSmithKline, OSI Pharmaceuticals, AstraZeneca, and CTI Pharmaceuticals. Bristol-Meyers Squibb developed Ixabepilone.

Correspondence: Dr. Johan Vansteenkiste



Back